Expertise in
13
conditions

Dr. Theodore W. Pollock

Oncology
Renal Treatment Centers West Inc
228 N Bliss Ave, 
Tahlequah, OK 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Expertise in
13
conditions
Renal Treatment Centers West Inc
228 N Bliss Ave, 
Tahlequah, OK 

Overview

Theodore Pollock is an Oncologist practicing medicine in Tahlequah, Oklahoma.

Dr. Pollock is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Squamous Cell Carcinoma of the Anal Canal (SCAC), and Anal Cancer.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 10 clinical trials. Dr. Pollock is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in OK

Hospital Affiliations

Northeastern Health System
Ohio State University State Health System
Cherokee Nation W W Hastings Indian Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Renal Treatment Centers West Inc
228 N Bliss Ave, Tahlequah, OK 74464
Other Locations
Southwestern Regional Medical Center
10109 E 79th St, Tulsa, OK 74133

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Enrollment Status: Recruiting
Publish Date: September 01, 2026
Intervention Type: Drug
Study Drugs: Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, Vemurafenib and Cobimetinib, Regorafenib, Olaparib, Pembrolizumab, Nivolumab and Ipilimumab, Abemaciclib, Afatinib, Talazoparib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Entrectinib, Larotrectinib, Tucatinib plus Trastuzumab Subcutaneous (SC)
Study Phase: Phase 2
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: May 18, 2026
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
Enrollment Status: Terminated
Publish Date: April 23, 2026
Intervention Type: Drug
Study Drugs: Alectinib, Brigatinib, Carboplatin, Ceritinib, Cisplatin, Crizotinib, Ensartinib, Lorlatinib, Pemetrexed
Study Phase: Phase 2
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Enrollment Status: Approved_for_marketing
Publish Date: January 17, 2025
Intervention Type: Drug
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 8 Less Clinical Trials

3 Total Publications

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
Journal: JAMA oncology
Published: June 04, 2021
Similar Doctors
Expertise in
45
conditions
Dr. Jihad Khattab
Hematology | Oncology
Expertise in
45
conditions
Dr. Jihad Khattab
Hematology | Oncology
Referral may be required

Saint Francis Cancer Center

11212 East 48th Street, 
Tulsa, OK 
 (52.0 miles away)
918-556-3000
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients

Jihad Khattab is a Hematologist and an Oncologist practicing medicine in Tulsa, Oklahoma. Dr. Khattab is highly rated in 45 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. Dr. Khattab is currently accepting new patients.

Expertise in
42
conditions
Dr. Syed F. Hassany
Hematology | Oncology
Expertise in
42
conditions
Dr. Syed F. Hassany
Hematology | Oncology
Referral may be required

Saint Francis Hospital Muskogee

300 Rockefeller Drive, 
Muskogee, OK 
 (28.0 miles away)
918-684-3374
Languages Spoken:
English, Urdu
See accepted insurances
Accepting New Patients

Syed Hassany is a Hematologist and an Oncologist practicing medicine in Muskogee, Oklahoma. Dr. Hassany is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Hassany is currently accepting new patients.

Expertise in
57
conditions
Expertise in
57
conditions
Referral may be required

Oklahoma Cancer Specialists And Research Institute

12697 E 51st St, 
Tulsa, OK 
 (51.0 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Roger Olsen, MD, is a board-certified, independent medical oncologist at Ascension St. John in Tulsa, Oklahoma. Dr. Olsen diagnoses and treats cancer using medications, such as chemotherapy, immunotherapy and targeted therapies. Every appointment with Dr. Olsen starts with a conversation. He takes the time to answer all your questions - big and small. Dr. Olsen is highly rated in 57 conditions, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Colorectal Cancer, Embryonal Tumor with Multilayered Rosettes, and Neuroepithelioma. Dr. Olsen is board certified in The American Board Of Internal Medicine - Medical Oncology. Dr. Olsen is currently accepting new patients.

Frequently Asked Questions about Dr. Theodore W. Pollock

How do I make an appointment with Dr. Theodore W. Pollock?

You can book an appointment with Dr. Theodore W. Pollock by calling their office at 918-506-6920. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Theodore W. Pollock a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Theodore W. Pollock is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Theodore W. Pollock specialize in?

While Dr. Theodore W. Pollock is a Oncology, they have specific expertise in Lung Cancer, Pleuropulmonary Blastoma, and Squamous Cell Carcinoma of the Anal Canal (SCAC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Theodore W. Pollock participate in research or clinical trials?

Yes. Dr. Theodore W. Pollock has published 3 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Theodore W. Pollock's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Theodore W. Pollock accept my insurance?

Dr. Theodore W. Pollock accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 918-506-6920 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pollock's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 87 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile